Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, delivered using the company's proprietary electroporation technology, are generating best-in-class immune responses, with therapeutic T cells exceeding other technologies. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase 2. Other phase 1 and preclinical programs target prostate, breast and lung cancers as well as HIV, influenza, malaria and hepatitis. Roche and Inovio have an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

Expert Comments:

Bret Jensen, Seeking Alpha (8/12/15)
"Inovio Pharmaceuticals Inc. recently just signed a major collaboration deal with pharma giant AstraZeneca through its subsidiary MedImmune. The deal provides Inovio with just under a $30M upfront payment and milestone payouts that could provide an additional $700M, which is greater than its current market capitalization."

Yi Chen, H.C. Wainwright & Co. (8/11/15)
"Inovio Pharmaceuticals Inc. announced yesterday that MedImmune, the global biologics research and development arm of AstraZeneca, agreed to acquire exclusive rights to Inovio's INO-3112 immunotherapy targeting human papillomavirus(HPV)-related cancers. . .Inovio will receive an upfront payment of $275M from MedImmune with $700M potential development and commercial milestones. . .and double-digit tiered royalties. . .the company reported revenue and earnings per share for Q2/15 of $5.3M and ($0.09), respectively, beating our projections of $2.5M and ($0.16). . .Inovio has $154.6M cash and investments as of June 30. Combined with the upfront payment from MedImmune, it should provide a runway to the end of 2018."

Charles Duncan, Piper Jaffray & Co. (8/10/15)
"Inovio Pharmaceuticals Inc. announced Q2/15 financials and a partnership with AstraZeneca worth up to $700M ($27.5M upfront plus potential development, regulatory and commercialization milestones) plus tiered double-digit royalties on sales. The partnership covers the development and commercialization of the company's human papillomavirus (HPV) immunotherapy INO-3112 (VGX-3100 plus IL-12 DNA) for cancer indications, while Inovio retains full rights for pre-cancer development. . .this further enhances our confidence in Inovio's DNA immunotherapy, and we reiterate our Overweight rating and $31 price target."

Thomas Shrader, Stifel Nicolaus (8/10/15)
"Inovio Pharmaceuticals Inc. announced a broad partnership with MedImmune to develop INO-3112 in combination with MedImmune's collection of immune-oncology molecules. . .MedImmune will fund development, allowing Inovio to leverage its cash to pursue its broad vaccine portfolio, which still includes VGX-3100 in pre-cancer. The company also reported a Q2/15 cash balance of $154M that does not include the $27.5M upfront payment as part of the MedImmune deal. We believe Inovio's potential reach into oncology based on DNA-based vaccines coupled with delivery of IL-12 is nearly unlimited. . .this deal with reasonable economics and a partner with very broad experience in the vaccine space makes sense."

Jason McCarthy, Maxim Group (8/10/15)
"Inovio Pharmaceuticals Inc. ended Q2/15 with $155M cash and is funded through 2018. Concurrent with reported earnings was the announcement of a partnership with MedImmune (division of AstraZeneca) for INO-3112 for the treatment of human papillomavirus(HPV)-driven cancers. MedImmune will make a $27.5M upfront payment, and Inovio could receive up to $700M in milestones as well as double-digit royalties. . .the partnership with MedImmune is the second big pharmaceutical deal for the company and is further validation of the potential of DNA-based vaccines and thus VGX-3100 to target HPV-related diseases. The VGX-3100 platform is turning into an HPV franchise for Inovio."

Jason Kolbert, Maxim Group (7/29/15)
"Inovio Pharmaceuticals Inc. announced that animals injected with DNA-based monoclonal antibody (dMAb) targeting dengue virus (causes hemorrhagic fever) had 100% survival following lethal challenge. While this is only preclinical data, combined with DARPA support for dMAbs targeting multiple infectious diseases (including Ebola), it changes how we can think about MAbs. . .DMAbs could be a disruptive technology for antibody-based therapeutics, a $50B market today, which includes blockbuster traditional MAbs like Keytruda, Yervoy, Humira and Remicade, to name a few."

More Expert Comments

Experts Commenting on This Company

Yi Chen, Managing Director of Equity Research – H.C. Wainwright & Co.
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Christopher James, Managing Director, Senior Equity Research Analyst – Brinson Patrick Securities Corporation
Jason Kolbert, Senior Analyst – Maxim Group
Jason Russ, Author Seeking Alpha
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw
Ross Silver, Co-Founder and Principal Analyst – Vista Partners
Jill Wahleithner, Fund Manager – Wasatch Funds
George Zavoico, Senior Equity Analyst – JonesTrading International Services LLC

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Inovio Pharmaceuticals Inc. Content